Clinical review report: Eculizumab (Soliris) Alexion Pharma Canada corporation : indication : adult patients with generalized myasthenia gravis
The objective of this report is to perform a systematic review of the beneficial and harmful effects of eculizumab for the treatment of adult patients who are AChR-antibody-positive and have refractory generalized myasthenia gravis, defined as having failed treatment with at least two immunosuppress...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, December 2020
|
| Edition: | Version: Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of eculizumab for the treatment of adult patients who are AChR-antibody-positive and have refractory generalized myasthenia gravis, defined as having failed treatment with at least two immunosuppressive therapies (ISTs), either in combination or as monotherapy, or having failed at least one IST and requiring chronic plasma exchange or intravenous immunoglobulin to control sympto02ms |
|---|---|
| Physical Description: | 1 PDF file (97 pages) |